ORIGINAL ARTICLE PURPOSEIn children the assessment of solid tumors' response to chemotherapy is based primarily on size reduction, which can be unreliable and a late marker, in the presence of necrosis. We aimed to establish whether apparent diffusion coefficient (ADC) values of childhood neuroblastomas show proportional changes in relation to chemotherapy response.
METHODSWe evaluated 15 pediatric patients with abdominopelvic neuroblastomas, who had undergone MRI before and after chemotherapy. Two radiologists retrospectively analyzed all images by drawing a round uniform region-of-interest in the solid/contrast-enhancing portion of the lesions in consensus.The ADC values from pre-and postchemotherapy images were compared.
RESULTSPostchemotherapy ADC values were significantly higher than those obtained before treatment (P < 0.05, for minimum, maximum, and median ADC values).
CONCLUSIONOur results support diffusion-weighted MRI as a promising noninvasive biomarker of therapeutic responses. To the best of our knowledge, this is the first report to compare diffusionweighted imaging findings before and after chemotherapy in childhood neuroblastic tumors. The ADC values of malignant masses are relatively lower than those of benign masses, although overlapping ADC values of malignant and benign lesions have also been reported (1, 6-12). Currently, in children the assessment of solid tumors' response to chemotherapy is based on size reduction; but this method can be unreliable as a marker, as tumors that shrink substantially may still be composed mainly of malignant cells (13,14).Here, we aimed to evaluate whether ADC values in viable portions of childhood neuroblastomas show any changes depending on tumor cellularity before and after chemotherapy. We hypothesized that an increase in ADC values over the course of chemotherapy could be used as a noninvasive marker of therapy response. To the best of our knowledge, this is the first report to compare DW-MRI findings before and after chemotherapy in childhood neuroblastic tumors.
Methods
PatientsWe retrospectively screened pediatric patients who had neuroblastic tumors and received treatment at our hospital between January 2009 and August 2013. We found 36 pediatric patients who underwent routine protocol-driven MRI assessment for solid tumors. Out of this group we acquired data from children who had intra-abdominal neuroblastic tumors that were diagnosed histopathologically. Our institution generally prefers MRI over computed tomography; however, due to capacity and time restrictions, not all patients undergo MRI both at primary diagnosis and at postchemotherapy follow-up. Only those patients who underwent MRI before and after chemotherapy were included in this study. In addition, exclusion criteria included any oncological (chemotherapy or radiotherapy) or surgical treatment before initial imaging. Consequently, we evaluated 15 patients between 4-138 months of age (mean, 37.8 months) including five females and 10 males. Thirteen patients were Stage 4 and two patients w...